We are live on
!
Find out more
CAM
ClariVest Asset Management Portfolio holdings
AUM
$980M
1-Year Est. Return
60.89%
This Fund
S&P 500
This Quarter
Est. Return
+12.64%
1 Year Est. Return
+60.89%
3 Year Est. Return
+106.43%
5 Year Est. Return
+337.88%
10 Year Est. Return
+1,091.18%
AUM
$3B
AUM Growth
+$175M
(+6.2%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-3.66%
Top 10 Holdings %
Top 10 Hldgs %
32.91%
Holding
863
New
116
Increased
124
Reduced
210
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$14.6M |
| 2 |
Olin
OLN
|
+$13.5M |
| 3 |
Dick's Sporting Goods
DKS
|
+$12.1M |
| 4 |
Old Dominion Freight Line
ODFL
|
+$9.78M |
| 5 |
Darden Restaurants
DRI
|
+$9.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$25.1M |
| 2 |
Eli Lilly
LLY
|
+$17M |
| 3 |
Procter & Gamble
PG
|
+$14.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$11.5M |
| 5 |
eBay
EBAY
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.15% |
| 2 | Consumer Discretionary | 18.06% |
| 3 | Healthcare | 13.51% |
| 4 | Communication Services | 9.6% |
| 5 | Industrials | 9.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
351
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $761K | 0.03% |
+53,857
| New | +$861K |
|
352
Navient
NAVI
$853M
| $759K | 0.03% |
39,291
| – | – |
|
|
OCDX
353
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $753K | 0.03% |
+35,195
| New | +$716K |
|
354
Alcoa
AA
$13.2B
| $751K | 0.03% |
+20,386
| New | +$741K |
|
355
Citi Trends
CTRN
$605M
| $749K | 0.02% |
+8,610
| New | +$792K |
|
356
Silicon Laboratories
SLAB
$7.23B
| $738K | 0.02% |
4,813
+8
| +0.2% | +$1.12K |
|
357
Vanda Pharmaceuticals
VNDA
$302M
| $735K | 0.02% |
34,137
| – | – |
|
358
SunCoke Energy
SXC
$797M
| $734K | 0.02% |
102,845
| – | – |
|
359
Xencor
XNCR
$1.55B
| $717K | 0.02% |
20,796
+47
| +0.2% | +$1.86K |
|
360
IQVIA
IQV
$39.3B
| $715K | 0.02% |
2,951
+2,945
| +49,083% | +$680K |
|
361
Modine Manufacturing
MOD
$10.4B
| $715K | 0.02% |
43,100
| – | – |
|
362
CEVA Inc
CEVA
$1.08B
| $714K | 0.02% |
15,100
| – | – |
|
|
MTEM
363
DELISTED
Molecular Templates, Inc.
MTEM
| $714K | 0.02% |
6,089
+3,447
| +130% | +$451K |
|
364
Wolverine World Wide
WWW
$1.55B
| $712K | 0.02% |
21,161
+5,328
| +34% | +$202K |
|
365
Ziff Davis
ZD
$1.98B
| $712K | 0.02% |
5,951
+14
| +0.2% | +$1.54K |
|
366
CBIZ
CBZ
$2.96B
| $711K | 0.02% |
21,680
+21,662
| +120,344% | +$724K |
|
367
Koppers
KOP
$969M
| $706K | 0.02% |
21,800
| – | – |
|
368
Cartesian Therapeutics
RNAC
$268M
| $706K | 0.02% |
+5,630
| New | +$670K |
|
369
Vipshop
VIPS
$7.53B
| $706K | 0.02% |
35,133
| – | – |
|
370
Seneca Foods Class A
SENEA
$1.21B
| $703K | 0.02% |
13,753
| – | – |
|
371
Mitek Systems
MITK
$834M
| $699K | 0.02% |
36,300
| – | – |
|
|
SRNE
372
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $691K | 0.02% |
71,229
-58,835
| -45% | -$469K |
|
|
EBIX
373
DELISTED
Ebix Inc
EBIX
| $689K | 0.02% |
20,353
+4
| +0% | +$124 |
|
|
BDSI
374
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $689K | 0.02% |
192,400
| – | – |
|
375
Hancock Whitney
HWC
$6.24B
| $684K | 0.02% |
15,404
| – | – |
|
Similar funds
GCAC
D
PP
FTIS
AIA
SEC
AFG
ECM
ClariVest Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, ClariVest Asset Management held 863 positions worth $3B, up 6.2% from $2.83B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
ClariVest Asset Management withdrew a net $110M in Q2 2021, closing 111 positions and reducing 210 holdings. Its most notable exit was Amgen, an estimated $25.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 34% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, ClariVest Asset Management opened a new position in Charles Schwab worth $15M.
- ClariVest Asset Management's largest Q2 2021 buy was Charles Schwab: 206,235 shares worth $15M.
- ClariVest Asset Management added most to Olin in Q2 2021, an estimated $13.5M increase.
- ClariVest Asset Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $17M.
- ClariVest Asset Management fully exited Amgen in Q2 2021, selling an estimated $25.1M.
- ClariVest Asset Management's ten largest holdings make up 33% of its $3B portfolio in Q2 2021.
- ClariVest Asset Management opened 116 new positions and closed 111 in Q2 2021.
- ClariVest Asset Management's portfolio value rose 6.2% quarter-over-quarter to $3B.
Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.